Advertisement
Screener

Dianthus Therapeutics, Inc. /DE/ (DNTH) Graph

DNTH Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $48.69M; Operating expenses $62.24M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $34.53M; Operating expenses $47.00M; Income tax (m).
  • 2025-12-31: Revenue $284.00K*; Research and development $59.90M*; Operating expenses $69.83M*; Income tax (m).
  • 2025-09-30: Revenue $396.00K; Research and development $32.49M; Operating expenses $40.68M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$48.69M$62.24M(m)-$50.22M
2026-03-31(m)$34.53M$47.00M(m)-$40.83M
2025-12-31$284.00K*$59.90M*$69.83M*(m)-$64.43M*
2025-09-30$396.00K$32.49M$40.68M(m)-$36.77M
2025-06-30$193.00K$26.25M$35.12M(m)-$31.63M
2025-03-31$1.16M$27.00M$34.34M(m)-$29.51M
2024-09-30$2.17M$25.54M$32.07M(m)-$25.17M
2024-06-30$1.86M$18.07M$24.07M(m)-$17.61M
2024-03-31$874.00K$13.08M$18.72M(m)-$13.75M
2023-09-30$924.00K$7.96M$16.68M(m)-$14.76M
2023-06-30(m)$10.25M$12.74M(m)-$11.14M
2023-03-31(m)$5.85M$8.16M(m)-$7.09M
2022-09-30$1.17M$7.22M$9.43M(m)-$7.78M
2022-06-30(m)$11.60M$18.08M(m)-$5.70M
2022-03-31(m)$16.55M$23.83M(m)-$4.88M
2021-09-30(m)$10.79M$18.25M(m)-$17.43M
2021-06-30(m)$11.13M$17.61M(m)-$16.93M
2021-03-31(m)$11.73M$18.70M(m)-$17.49M
2020-09-30$0.00$11.79M$18.38M(m)-$17.68M
2020-06-30$0.00$12.61M$20.01M(m)-$19.08M
2020-03-31$0.00$13.96M$21.24M(m)-$20.01M
2019-12-31$0.00(m)(m)(m)-$23.24M
2019-09-30$0.00$16.52M$22.64M(m)-$20.99M
2019-06-30$0.00$13.43M$19.34M(m)-$17.71M
2019-03-31$0.00$10.54M$16.35M(m)-$14.83M
2018-12-31$0.00(m)(m)(m)-$16.68M
2018-09-30$0.00$11.42M$16.70M$0.00-$16.02M
2018-06-30$0.00$9.68M$14.03M$0.00-$13.66M
2018-03-31$0.00$7.85M$11.31M(m)-$11.16M
2017-12-31$0.00(m)(m)(m)-$8.04M
2017-09-30$0.00$5.21M$7.01M$0.00-$6.91M
2017-06-30$0.00$13.82M$15.73M$0.00-$15.73M
2017-03-31$0.00(m)(m)(m)-$4.81M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$83.21M$109.24M(m)-$91.05M
2025-06-30$1.36M$53.25M$69.46M(m)-$61.14M
2024-06-30$2.74M$31.15M$42.78M(m)-$31.36M
2023-06-30(m)$16.10M$20.90M(m)-$18.23M
2022-06-30(m)$28.15M$41.92M(m)-$40.22M
2021-06-30(m)$22.86M$36.31M(m)-$34.42M
2020-06-30$0.00$26.57M$41.26M(m)-$39.09M
2019-06-30$0.00$23.97M$35.69M(m)-$32.54M
2018-06-30$0.00$17.53M$25.33M$0.00-$24.82M
2017-06-30$0.00$17.14M$20.54M$0.00-$20.54M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$1.75M$85.74M$110.14M(m)-$97.91M
2024-09-30$4.91M$56.69M$74.86M(m)-$56.53M
2023-09-30$2.37M$24.06M$37.59M(m)-$32.99M
2022-09-30$5.24M$19.55M$24.25M(m)-$18.36M
2021-09-30(m)$33.65M$54.55M(m)-$51.84M
2020-09-30$0.00$38.36M$59.64M(m)-$56.77M
2019-09-30$0.00$40.49M$58.33M(m)-$53.53M
2018-09-30$0.00$28.95M$42.03M$0.00-$40.84M
2017-09-30$0.00$22.35M$27.56M$0.00-$27.45M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$2.04M$145.64M$179.97M$0.00-$162.34M
2024-12-31$6.24M$83.11M$108.10M$0.00-$84.97M
2023-12-31$2.83M$32.84M$51.00M$0.00-$43.55M
2022-12-31$6.42M$29.38M$36.12M$0.00-$28.48M
2021-12-31$1.48M$12.61M$14.56M$0.00-$13.11M
2020-12-31(m)$50.62M$78.70M$0.00-$74.94M
2019-12-31$0.00$59.21M$82.97M$0.00-$76.77M
2018-12-31$0.00$41.34M$59.96M$0.00-$57.52M
2017-12-31$0.00$27.90M$35.73M$0.00-$35.49M
2016-12-31$0.00$5.78M$9.27M$0.00-$9.43M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Erasca, Inc. (ERAS)United States$5.073B-19.96
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51